Introduction
Renal cell carcinoma (RCC) is the most common type of kidney cancer and accounts for about 90%-95% of kidney cancer cases. 1 It usually starts with weight loss, flank pain, blood in the urine, high blood pressure, fever, feeling unwell, and night sweats. 2 RCC is responsible for 2%-3% of all malignancies in adult, ranking 7th and 9th in common cancer cases among men and women, respectively. 3 Globally, RCC induces ~2,09,000 new cases and results in 1,02,000 deaths per year. 4 When RCC is diagnosed, in ~30% of cases, the cells spread into the ipsilateral renal vein, and in 5%-10% of cases, it spreads to the inferior vena cava. 5 RCC commonly metastasizes to the adrenal glands, lymph nodes, liver, lungs, brain, or bones, and targeted therapy can be used to improve the outcome of metastatic RCC. 6 Clear cell renal cell carcinoma (ccRCC) is the most submit your manuscript | www.dovepress.com
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Wang et al common type of RCC, which is responsible for 75% of the cases. 7 Therefore, investigating the mechanisms of ccRCC is important for improving therapies.
In patients with low-risk ccRCC, the expression of BRCA1-associated protein-1 (BAP1) can serve as a prognostic marker independently. 8, 9 Galectin-1 (GAL1) regulates migration and invasion of ccRCC via the hypoxia-inducible factor-1α (HIF-1α)-mammalian target of rapamycin (mTOR) signaling axis; thus, GAL1 is a promising prognostic indicator and therapeutic target for the disease. 10 Previous studies report that both the mRNA and protein levels of AT-rich interactive domain 1A (ARID1A) have statistical significance in predicting the prognosis of ccRCC. 11, 12 Vascular endothelial growth factor A (VEGFA), which is a critical angiogenic cytokine, plays an important role in tumor angiogenesis and may be a key target for cancer therapy. 13 As an endothelial Notch ligand, delta-like ligand 4 (DLL4) plays a critical role in regulating tumor angiogenesis and thus is a potential antiangiogenesis target in clinical applications.
14 RCC is a typical hypervascular tumor, and its tumor cells can promote tumor growth and progression through producing pro-angiogenesis factors. 15 However, the prognostic genes involved in ccRCC have not been fully reported. Thus, this study was designed to investigate the genes associated with the prognosis of ccRCC, focusing on the roles of VEGFA and DLL4 in ccRCC.
In this study, the mRNA-sequencing (mRNA-seq) data of kidney renal clear cell carcinoma (KIRC) were obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed genes (DEGs) between tumor samples and adjacent normal samples were identified, and then enrichment analysis was performed. Followed by protein-protein interaction (PPI) network analysis, protein subcellular localization, subgroup analysis, and survival analysis were successively performed to explore the key genes involved in the prognosis of ccRCC. Finally, VEGFA and DLL4 expression levels were detected by real-time quantitative PCR (qRT-PCR).
Materials and methods
Date source
The level 3 mRNA-seq data (downloaded in November 2016) of KIRC were downloaded from TCGA (https://cancergenome.nih.gov/) database, including 469 tumor samples and 68 adjacent normal samples. Meanwhile, clinical information including age, gender, race, tumor stage, survival time, and outcome were also obtained.
Data preprocessing and Degs screening
Using the edgeR package (version 3.4, http://www.bioconductor. org/packages/release/bioc/html/edgeR.html) 16, 17 19 The genes with FDR ,0.05 and |log 2 fold change (FC)| .2 were identified as DEGs.
Functional and pathway enrichment analysis
Gene Ontology (GO, http://www.geneontology.org) database can be applied for performing functional enrichment for genes and gene products. 20 The Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.genome.jp/kegg/) database, which includes known genes and corresponding biochemical functionalities, can be used for pathway enrichment analysis. 21 BioCloud is an online platform (http://www. biocloudservice.com) that was developed for computing high-throughput data. Using the multifaceted analysis tool for human transcriptome tool in the BioCloud platform, the DEGs were performed with functional and pathway enrichment analyses. The p-value ,0.01 was set as the cutoff criterion.
PPi network analysis and protein subcellular localization
The intersection of the PPI pairs included in Mentha (http:// mentha.uniroma2.it/about.php), 22 BioGRID (https://wiki. thebiogrid.org/), 23 and HPRD (http://www.hprd.org/) 24 databases was taken as background, and then the DEGs were mapped into the background to obtain their PPI pairs. Subsequently, the PPI network for the DEGs was visualized by Cytoscape software (http://www.cytoscape.org). 25 Using the CytoNCA plugin (version 2.1.6, http://apps.cytoscape. org/apps/cytonca) 26 in Cytoscape software, betweenness centrality (BC), degree centrality (DC), and closeness centrality (CC) of the nodes in PPI network were analyzed to further identify hub nodes. 27 In addition, the information of human protein subcellular localization were obtained from InnateDB database (http://www.innatedb.com/), 28 including extracellular space, cell surface, cytoplasm, plasma membrane, and nucleus. Afterward, protein subcellular localizations of the nodes in the PPI network were identified.
subgroup analysis based on tumor stage
To further explore DEGs, KIRC tumor samples were divided into four groups (stages I, II, III, and IV) based on their tumor 
Differential expression analysis and subgroup analysis of validation dataset
The raw CEL files and annotation files under GSE53757, which were sequenced on the platform of GPL570 [HG-U133_ Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array, were obtained from Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) database (downloaded in November 2016). GSE53757 included 72 ccRCC tumor samples and 72 adjacent normal samples. After the raw data of GSE53757 were read by the affy package (version 1.50.0, http://www.bioconductor.org/packages/release/bioc/html/ affy.html) 29 in R, they were performed with background correction, normalization, and expression calculation using robust multi-array average (RMA) method. 30 Based on the annotation files, the probes having no matched gene symbol were eliminated. For probes having the same gene symbol, their average value was taken as the final expression value of the gene. Finally, differential expression analysis and subgroup analysis were performed separately for the ccRCC tumor samples and adjacent normal samples using limma package 18 with FDR ,0.05 and |log 2 FC| .2 as the thresholds.
survival analysis
To obtain prognosis-associated genes, the intersection DEGs between TCGA dataset and GSE53757 were identified. Then the intersection DEGs were divided into groups with high expression and low expression based on their medians. Using Cox model, 31 variables such as age, gender, and tumor stage were adjusted. The genes with p-value ,0.05 were taken as prognosis-associated genes. The hazard ratios (HRs) for survival were predicted for the prognosis-associated genes. In addition, high-expressed genes with HR .1 and low-expressed genes with HR ,1 were identified, and then Kaplan-Meier (KM) survival curve were drawn.
qrT-Pcr analysis
A total of 11 pairs of ccRCC tumor samples and adjacent normal samples were obtained from our hospital. This study was approved by the ethic committee of The Fifth People's Hospital of Shanghai, Fudan University, and written informed consent was obtained from relevant patients. Total RNA was isolated from the samples with RNAiso Plus (TaKaRa, Tokyo, Japan) following the manufacturer's manual. Followed by the concentration and quality of total RNA were detected using microplate reader (Tecan, Mannedorf, Switzerland). Subsequently, first-strand cDNA was synthesized using a reverse transcription kit (TaKaRa) and then stored at -20°C.
For qRT-PCR experiments, primers were designed and synthesized separately by Primer Premier 6.0 software (Premier Software Inc., Cherry Hill, NJ, USA) and Sangon Biotech Co., Ltd (Shanghai, China) (Table 1) , respectively. The expression levels of VEGFA and DLL4 in ccRCC tumor samples and adjacent normal samples were measured using SYBR green kit (Thermo Fisher Scientific, Waltham, MA, USA). The 10 µL amplification system included 5 µL SYBR Premix EX Taq (2x)
statistical analysis
Based on the 2-ΔΔCt method, 32 the expression levels of VEGFA and DLL4 were analyzed. All results were shown as mean ± standard error of mean (SEM). GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analysis and drawing pictures. The p,0.05 was taken as the threshold for significant difference.
Results
Deg screening
A total of 1,984 DEGs were identified in the KIRC tumor samples in relative to adjacent normal samples, including 806 upregulated genes (including VEGFA and DLL4) and 1,178 downregulated genes. There were more downregulated genes than upregulated genes.
Functional and pathway enrichment analysis
Both the upregulated genes and downregulated genes were performed with enrichment analysis. The top 10 GO terms and pathways are shown in Figure 1A and B, respectively. For the upregulated genes, the enriched GO terms mainly included immune response, regulation of immune response, and inflammatory response. Meanwhile, the pathways enriched for the upregulated genes mainly included
Staphylococcus aureus infection, natural killer cell-mediated cytotoxicity, and cytokine-cytokine receptor interaction. Besides, the GO terms enriched for the downregulated genes mainly included excretion, ion transmembrane transport, 
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Prognostic genes for ccrcc and chloride transmembrane transport. Moreover, the downregulated genes were enriched in pathways such as neuroactive ligand-receptor interaction, protein digestion and absorption, and tyrosine metabolism.
PPi network analysis and protein subcellular localization
A total of 729 nodes and 1,105 interactions were obtained from the intersection of the PPI pairs included in Mentha, BioGRID, and HPRD databases. Then the PPI network involving 337 upregulated genes and 392 downregulated genes was constructed (Figure 2) . Combined with BC, CC, and DC scores, the top 10 nodes are listed in Table 2 (Figure 3) showed that the common DEGs among the four comparison groups were in majority. Importantly, VEGFA were differentially expressed in all the four comparison groups, and DLL4 had significantly differential expression in stage I versus normal, stage II versus normal, and stage III versus normal comparison groups (Figure 4 ).
Figure 2
The protein-protein interaction network constructed for the differentially expressed genes. circles and diamonds represent upregulated genes and downregulated genes, respectively. green, blue, purple, brown, red, and gray represent nodes located in cell surface, cytoplasm, extracellular space, nucleus, plasma membrane, and unknown, respectively. The size of a node indicates its degree.
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Differential expression analysis and subgroup analysis of validation dataset
After the raw data of GSE53757 were preprocessed, a total of 398 DEGs were identified in ccRCC tumor samples compared with adjacent normal samples, including 147 upregulated genes (such as VEGFA) and 251 downregulated genes. Based on the tumor stage, ccRCC tumor samples were also divided into four groups (stages I, II, III, and IV). Then subgroup analysis was performed for the ccRCC tumor samples and adjacent normal samples, finding that VEGFA was significantly upregulated in stages I, II, and III ccRCC tumor samples ( Figure 5 ).
survival analysis
There were 270 intersection DEGs between TCGA dataset and GSE53757, including 103 upregulated genes and 167 downregulated genes. Then a total of 40 prognosisassociated genes were identified from the intersection DEGs. The KM survival curves for the top four prognosis-associated genes (according to p-values) (including aldehyde dehydrogenase 6 family, member A1, ALDH6A1; WD repeat domain 72, WDR72; phospholipase C-like 1, PLCL1; and TIMP metallopeptidase inhibitor 1, TIMP1) are shown in Figure 6 .
qrT-Pcr analysis
Furthermore, the expression levels of DLL4 and VEGFA in ccRCC tumor samples and adjacent normal samples were detected by using qRT-PCR. In tumor samples, the expression levels of DLL4 (p,0.001, Figure 7A ) and VEGFA (p,0.01, Figure 7B ) were significantly upregulated in relative to adjacent normal samples.
Discussion
In this study, a total of 1,984 DEGs (including upregulated VEGFA and DLL4) were identified in the KIRC tumor samples in relative to adjacent normal samples. Subgroup analysis for the KIRC tumor samples showed that VEGFA were differentially expressed in all the four comparison groups, and DLL4 had significantly differential expression in stage I versus normal, stage II versus normal, and stage III versus normal comparison groups. Meanwhile, subgroup analysis for the validation dataset showed that VEGFA was significantly upregulated in stages I, II, and III ccRCC tumor samples. In addition, qRT-PCR analysis confirmed that the expression levels of DLL4 and VEGFA were significantly upregulated in tumor samples. 
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Prognostic genes for ccrcc In RCC, increased serum level of VEGF is correlated with adverse survival and can serve as a prognostic factor. 33 VEGF expression is associated with tumor stage and prognosis, suggesting that VEGF functions in the growth and progression of RCC. 34, 35 Huang et al reported that the activation of DLL4/Notch signaling and the interaction of endothelium and cells contribute to the progression of RCC.
36
DLL4 blockade has a promising antitumor activity in RCC patient-derived tumors, and the simultaneous targeting of the VEGF and DLL4 signaling pathways has a combination benefit. 37 Therefore, VEGFA and DLL4 might be prognostic genes for ccRCC.
Besides, VEGFA was located in extracellular space and had interactions with PGF and ANGPT2 in the PPI network. Angiogenic protein PGF belongs to the VEGF family, and anti-PGF antibody may be used as antiangiogenic agent that is minor toxicity when combined with anti-VEGF strategies. 38 Plasma levels of PGF have significant correlation with the clinical features and VEGF levels and thus can be used as an independent prognostic factor for RCC. 39 Plasma ANGPT2 concentration is increased in RCC patients, and ANGPT2 can serve as a promising target for the treatment of tyrosine kinase-resistant RCC. 40 Through targeting oncogenes ANGPT2 and neural precursor cell expressed, developmentally downregulated 9 (NEDD9), miR-145 acts as tumor suppressor and therapeutic target in patients with RCC. 41 By activating Tie2 receptor tyrosine kinase, ANGPT2 protects tumor endothelial cells and suppresses the antivascular effects of VEGF inhibition. 42 This indicates that PGF and ANGPT2 might be involved in the prognosis of ccRCC through interacting with VEGFA.
Moreover, 40 prognosis-associated genes were identified from the intersection DEGs between TCGA dataset and GSE5375, and TIMP1 was among the top four prognosisassociated genes. Through upregulating matrix metalloproteinase-2 (MMP-2) and MMP-9 and downregulating TIMP1, S-phase kinase-associated protein-2 (SKP2) signaling pathway contributes to the invasion and metastasis of RCC cells. 43, 44 Elevated protein levels of MMP2, MMP9, TIMP1, and TIMP2 are related to shortened patient survival and thus predict poor prognosis in RCC. 45 MMPs and TIMPs function in maintaining extracellular matrix homeostasis, and TIMP1 and TIMP2 levels are relevant in RCC. 46 By upregulating TIMP1 and TIMP2, Rac signaling inhibits the invasion of epithelial tumor cells in RCC patients. 47 Thus, TIMP1 might also be associated with the prognosis of ccRCC.
Conclusion
A series of bioinformatics analyses were carried out, finding a total of 1,984 DEGs in the KIRC tumor samples. Besides, VEGFA and DLL4 might be prognostic genes for ccRCC. Furthermore, PGF, ANGPT2, and TIMP1 might also be related to the prognosis of ccRCC patients. However, in-depth experimental research studies should be performed to confirm our findings.
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